Tags

Type your tag names separated by a space and hit enter

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Mol Psychiatry 2004; 9(7):705-10MP

Abstract

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) beta-amyloid(1-42) (Abeta(1-42)) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Abeta(1-42) and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Abeta(1-42) and CSF tau. The levels of CSF tau were increased, whereas levels of Abeta(1-42) were decreased in MCI subjects. Abeta(1-42) predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Abeta(1-42), but not other predictor variables (tau protein, gender, age, apolipoprotein E epsilon4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P<0.05). Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects.

Authors+Show Affiliations

Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia Research Section and Memory Clinic, Ludwig-Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14699432

Citation

Hampel, H, et al. "Value of CSF Beta-amyloid1-42 and Tau as Predictors of Alzheimer's Disease in Patients With Mild Cognitive Impairment." Molecular Psychiatry, vol. 9, no. 7, 2004, pp. 705-10.
Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9(7):705-10.
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., ... Buerger, K. (2004). Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 9(7), pp. 705-10.
Hampel H, et al. Value of CSF Beta-amyloid1-42 and Tau as Predictors of Alzheimer's Disease in Patients With Mild Cognitive Impairment. Mol Psychiatry. 2004;9(7):705-10. PubMed PMID: 14699432.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. AU - Hampel,H, AU - Teipel,S J, AU - Fuchsberger,T, AU - Andreasen,N, AU - Wiltfang,J, AU - Otto,M, AU - Shen,Y, AU - Dodel,R, AU - Du,Y, AU - Farlow,M, AU - Möller,H-J, AU - Blennow,K, AU - Buerger,K, PY - 2003/12/31/pubmed PY - 2005/1/5/medline PY - 2003/12/31/entrez SP - 705 EP - 10 JF - Molecular psychiatry JO - Mol. Psychiatry VL - 9 IS - 7 N2 - Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) beta-amyloid(1-42) (Abeta(1-42)) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Abeta(1-42) and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Abeta(1-42) and CSF tau. The levels of CSF tau were increased, whereas levels of Abeta(1-42) were decreased in MCI subjects. Abeta(1-42) predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Abeta(1-42), but not other predictor variables (tau protein, gender, age, apolipoprotein E epsilon4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P<0.05). Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects. SN - 1359-4184 UR - https://www.unboundmedicine.com/medline/citation/14699432/Value_of_CSF_beta_amyloid1_42_and_tau_as_predictors_of_Alzheimer's_disease_in_patients_with_mild_cognitive_impairment_ L2 - http://dx.doi.org/10.1038/sj.mp.4001473 DB - PRIME DP - Unbound Medicine ER -